NA
KALV

Neuburgh Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Neuburgh Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$10K Hold
836
– – ﹤0.01% 909
2019
Q2 		$19K Hold
836
– – ﹤0.01% 890
2019
Q1 		$24K Hold
836
– – ﹤0.01% 880
2018
Q4 		$17K Buy
+836
New +$16.8K ﹤0.01% 866

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuburgh Advisers's KALV Position: Q3 2019 in Review

Neuburgh Advisers held its KalVista Pharmaceuticals (KALV) position steady in Q3 2019 at 836 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #909.

Neuburgh Advisers first reported a position in KALV in Q4 2018 and has held it in 4 quarters since. The position peaked at $24K in Q1 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

  • Neuburgh Advisers held 836 shares of KalVista Pharmaceuticals worth $10K as of Q3 2019.
  • Neuburgh Advisers left its KalVista Pharmaceuticals share count unchanged in Q3 2019.
  • KalVista Pharmaceuticals made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #909 holding.
  • Neuburgh Advisers first reported a position in KalVista Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's KalVista Pharmaceuticals position peaked at $24K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.